RecruitingNCT06521476
Testing acetazolamide for sleep-related breathing problems during opioid treatment
About this title
Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder
Read the official source — NCT06521476Medication studyAges 18–100United StatesAddiction
Understand this study
Who could participate?
Listed age limits: 18 years to 100 years.
What will I do during this study?
Depending on your group, you take one 250 mg acetazolamide tablet or a matching placebo (an inactive comparison treatment) each evening for seven days.
- Listed locations
- PittsburghSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: September 30, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 40
- Sponsor
- Sanjay R Patel
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 100 Years
- Official registry ID
- NCT06521476
- Official title
Show the full official title
Impact of Acetazolamide on Central Sleep Apnea Patients Receiving Medication for Opioid Use Disorder
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Pittsburgh
Questions about this study
Who is behind this study?
The study sponsor is Sanjay R Patel.
Does this study involve medication?
Yes. The study involves medication, including Acetazolamide and Placebo.
Who can participate?
Listed age limits: 18 years to 100 years.
Is this study still recruiting?
The registry lists this study as recruiting.
